Avadel Pharmaceuticals plc (NASDAQ:AVDL) currently has a daily average trading volume of 1.30M but it saw 2382166 shares traded in last market. With a market cap of 1.51B USD, the company’s current market price of $15.74 came falling about -2.24 while comparing to the previous closing price of $16.10. In past 52 weeks, the stock remained buoying in the range of price level as high as $19.09 and as low as $9.50. In the recent trading on the day, stock has struck highest price mark of $15.4201 while lowest mark touched by it was $17.298.
Taking a look at 20-day trading activity of Avadel Pharmaceuticals plc (AVDL) gives us an average price of $16.34, while its current price level is -17.55% below from 52-week high level whereas it is 65.68% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $15.64 while that of 200 days or SMA-200 reads an average of $14.81. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.17% during that period while stretching the period over a month that decreases to 4.11%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 45.57 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Rodman & Renshaw which initiated the stock as “Buy” in its note to investors issued on June 12, 2024, recommending a price target of $27 for it. Needham issued its recommendations for the stock as it reiterated the price target for the stock in the range of between $20 and $22.
Over the week, AVDL’s stock price is moving -4.66% down while it is -2.36% when we observe its performance for the past one month. Year-to-date it is 11.47% up and over the past year, the stock is showing an upside performance of 16.51%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -0.41 beaten by the consensus estimate of -0.37 for the same. In next quarter, company is expected to be making quarterly sales of $57.31M as analysts are expecting the sales for current fiscal year at $171.56M and seeing the company making $303.53M in sales next year. Moreover, analysts are in estimates of $48.25M for current-quarter revenue.
Currently, Avadel Pharmaceuticals plc’s total number of outstanding shares is 96.20M with 4.78% of that held by the insiders while 79.14% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -137.37% and return on equity (ROE) at -779.92%. It has a 25.29 of forward P/E ratio. Stock’s beta reads 1.52. Stock has a price to book (P/B) ratio of 19.30 while price to sale or P/S ratio amounts to 27.46. Its return on asset (ROA) is -101.63% on average.
